Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial

被引:62
|
作者
Pinsky, PF
Kramer, BS
Reding, D
Buys, S
机构
[1] NCI, Div Canc Prevent, Bethesda, MD 20892 USA
[2] NIH, Off Dis Prevent, Off Director, Bethesda, MD 20892 USA
[3] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI 54449 USA
[4] Univ Utah, Sch Med, Dept Internal Med, Div Hematol Oncol, Salt Lake City, UT USA
关键词
ethnic groups; family characteristics; genetic predisposition to disease; neoplasms; questionnaires; sex factors;
D O I
10.1093/aje/kwg043
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The authors analyzed data from almost 150,000 subjects aged 55-74 years enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial who completed a self-administered baseline questionnaire (1993-2001) that included items about family history of cancer. Male respondents reported significantly less family history of cancer than females. The relative underreporting by male respondents relative to females was greater for female family members (28% lower for sisters and 21% lower for mothers) than for male family members (13% lower for brothers and 9% lower for fathers). Black, Hispanic, and Asian respondents reported significantly less family history of cancer than Whites. Reported family history prevalences for parents decreased with respondents' age, while those for siblings increased with respondents' age. The four most commonly reported cancers in families were breast (11.8%), lung (10.1%), colorectal (9.4%), and prostate (7.3%) cancer. Expected prevalences in family members of history of cancer overall and history of specific types of cancer were calculated using incidence rates and life table data obtained from the Surveillance, Epidemiology, and End Results Program. Overall, the ratio of reported cancer rates to expected cancer rates in family members was approximately 0.7. Liver, bone, stomach, and brain cancer had greater-than-average reported:expected ratios, while lymphoma, bladder cancer, melanoma, and testicular cancer had lower-than-average ratios.
引用
收藏
页码:792 / 799
页数:8
相关论文
共 50 条
  • [31] Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
    Stallings, FL
    Ford, ME
    Simpson, NK
    Fouad, M
    Jernigan, JC
    Trauth, JM
    Miller, DS
    [J]. CONTROLLED CLINICAL TRIALS, 2000, 21 (06): : 379S - 389S
  • [32] THE PROSTATE, LUNG, COLORECTAL, AND OVARIAN-CANCER SCREENING TRIAL OF THE NATIONAL-CANCER-INSTITUTE
    GOHAGAN, JK
    PROROK, PC
    KRAMER, BS
    HAYES, RB
    CORNETT, JE
    [J]. CANCER, 1995, 75 (07) : 1869 - 1873
  • [33] Colorectal cancers not detected by screening flexible sigmoidoscopy in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
    Schoen, Robert E.
    Pinsky, Paul F.
    Weissfeld, Joel L.
    Yokochi, Lance A.
    Church, Timothy
    Laiyemo, Adeyinka O.
    Bresalier, Robert
    Hickey, Tom
    Riley, Thomas
    Prorok, Philip C.
    [J]. GASTROINTESTINAL ENDOSCOPY, 2012, 75 (03) : 612 - 620
  • [34] Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial
    Miller, Eric A.
    Pinsky, Paul F.
    Black, Amanda
    Andriole, Gerald L.
    Pierre-Victor, Dudith
    [J]. PROSTATE, 2018, 78 (11): : 830 - 838
  • [35] Hormone Replacement Therapy and Colorectal Cancer Incidence and Mortality in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
    Symer, Matthew M.
    Wong, Natalie Z.
    Abelson, Jonathan S.
    Milsom, Jeffrey W.
    Yeo, Heather L.
    [J]. CLINICAL COLORECTAL CANCER, 2018, 17 (02) : E281 - E288
  • [36] Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
    Koutros, Stella
    Meyer, Tamra E.
    Fox, Stephen D.
    Issaq, Haleem J.
    Veenstra, Timothy D.
    Huang, Wen-Yi
    Yu, Kai
    Albanes, Demetrius
    Chu, Lisa W.
    Andriole, Gerald
    Hoover, Robert N.
    Hsing, Ann W.
    Berndt, Sonja I.
    [J]. CARCINOGENESIS, 2013, 34 (10) : 2281 - 2285
  • [37] Dietary intake of isoflavones and coumestrol and the risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
    Reger, Michael K.
    Zollinger, Terrell W.
    Liu, Ziyue
    Jones, Josette F.
    Zhang, Jianjun
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (04) : 719 - 728
  • [38] Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial
    Ahn, Jiyoung
    Albanes, Demetrius
    Peters, Ulrike
    Schatzkin, Arthur
    Lim, Unhee
    Freedman, Michal
    Chatterjee, Nilanjan
    Andriole, Gerald L.
    Leitzmann, Michael F.
    Hayes, Richard B.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (12) : 2623 - 2630
  • [39] Dietary consumption of tea and the risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Thomas, Robert J.
    McConnachie, Alex
    Stanley, Bethany
    Williams, Madeleine
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Vitamin K intake and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial
    Hoyt, Margaret
    Reger, Michael
    Marley, Andrew
    Fan, Hao
    Liu, Ziyue
    Zhang, Jianjun
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 2019, 109 (02): : 392 - 401